Retraction to: Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: A 1-year open-label trial: Effect of blonanserin in schizophrenia (Psychiatry and Clinical Neurosciences, (2014), 68, 12, (841-849), 10.1111/pcn.12202);Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: A 1-year open-label trial

Psychiatry and Clinical Neurosciences

Volumn 68, Issue 12, 2014, Pages 841-849

  Ninomiya, Yuriko ^a   Miyamoto, Seiya ^a   Tenjin, Tomomi ^a   Ogino, Shin ^a   Miyake, Nobumi ^a   Kaneda, Yasuhiro ^b   Sumiyoshi, Tomiki ^c   Yamaguchi, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Iwaki Clinic   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

blonanserin; cognition; first episode schizophrenia; second generation antipsychotics; subjective well being

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BLONANSERIN; CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYPNOTIC AGENT; LOW DENSITY LIPOPROTEIN; PROLACTIN; TRIACYLGLYCEROL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA JAPANESE VERSION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; LONG TERM CARE; MALE; MENTAL PATIENT; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIA QUALITY OF LIFE JAPANESE VERSION; SIDE EFFECT; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC TREATMENT SCALE SHORT FORM JAPANESE VERSION; VERBAL MEMORY; WEIGHT GAIN; FOLLOW UP; TIME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIPERAZINES; PIPERIDINES; QUALITY OF LIFE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84916208120     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12533     Document Type: Erratum

References (39)

1. Miyamoto S, Merrill DB, Lieberman JA, Fleischhacker WW, Marder SR,. Antipsychotic drugs. In:, Tasman A, Kay J, Lieberman JA, First MB, Maj M, (eds). Psychiatry. 3rd edn. John Wiley & Sons, Chichester, 2008; 2161-2201.
2. Tenjin T, Miyamoto S, Ninomiya Y, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 2013; 9: 587-594.
3. Murasaki M,. Clinical evaluation of blonanserin for schizophrenia: A randomized controlled study comparing blonanserin with haloperidol. Jpn. J. Clin. Psychopharmacol. 2007; 10: 2059-2079.
4. Miura S,. Clinical evaluation of blonanserin for schizophrenia: A randomized controlled study comparing blonanserin with risperidone. Jpn. J. Clin. Psychopharmacol. 2008; 11: 297-314.
5. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y,. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625.
6. Yang J, Bahk WM, Cho HS, et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175.
7. Deeks ED, Keating GM,. Blonanserin: A review of its use in the management of schizophrenia. CNS Drugs 2010; 24: 65-84.
8. Kishi T, Matsuda Y, Nakamura H, Iwata N,. Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. J. Psychiatr. Res. 2013; 47: 149-154.
9. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001; 50: 79-88.
10. Vothknecht S, Schoevers RA, de Haan L,. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: A review. Aust. N. Z. J. Psychiatry 2011; 45: 182-192.
11. Miyake N, Miyamoto S, Takeuchi A, et al. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidone. Jpn. J. Clin. Psychopharmacol. 2008; 11: 315-326.
12. Tenjin T, Miyamoto S, Miyake N, et al. Effect of blonanserin on cognitive function in antipsychotic-naive first-episode schizophrenia. Hum. Psychopharmacol. 2012; 27: 90-100.
13. American Psychiatric Association. Diagnostic Criteria from DSM-IV-TR. American Psychiatric Association, Washington, DC, 2000.
14. Watanabe M, Matsumura H,. Reliability and validity of Subjective Well-being under Neuroleptics drug treatment Short form, Japanese version (SWNS-J). Jpn. J. Clin. Psychopharmacol. 2003; 6: 905-912.
15. Kaneda Y, Imakura A, Fujii A, Ohmori T,. Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Res. 2002; 113: 107-113.
16. Kay SR, Fiszbein A, Opler LA,. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261-276.
17. Lindenmayer JP, Bernstein-Hyman R, Grochowski S,. Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. 1994; 182: 631-638.
18. Kim JH, Kim SY, Lee J, Oh KJ, Kim YB, Cho ZH,. Evaluation of the factor structure of symptoms in patients with schizophrenia. Psychiatry Res. 2012; 197: 285-289.
19. Kim JH, Lee J, Kim YB, Han AY,. Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine. Compr. Psychiatry 2014; 55: 708-713.
20. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T,. Brief assessment of cognition in schizophrenia: Validation of the Japanese version. Psychiatry Clin. Neurosci. 2007; 61: 602-609.
21. Kaneda Y, Sumiyoshi T, Nakagome K, et al. Evaluation of cognitive functions in a normal population in Japan using the Brief Assessment of Cognition in Schizophrenia Japanese version (BACS-J). Seishin Igaku (Clinical Psychiatry) 2013; 55: 167-175.
22. Inada T,. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage., Yagi G, (ed.), Seiwa shoten, Tokyo, 1996.
23. Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG,. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr. Scand. 2007; 115: 106-113.
24. Van Putten T, May PR, Marder SR, Wittmann LA,. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry 1981; 38: 187-190.
25. Karow A, Naber D,. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002; 162: 3-10.
26. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008; 371: 1085-1097.
27. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J. Clin. Psychiatry 2006; 67: 1690-1697.
28. Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr. Scand. 2008; 118: 220-229.
29. Uzenoff SR, Brewer KC, Perkins DO, Johnson DP, Mueser KT, Penn DL,. Psychological well-being among individuals with first-episode psychosis. Early Interv. Psychiatry 2010; 4: 174-181.
30. Strauss GP, Sandt AR, Catalano LT, Allen DN,. Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia. Compr. Psychiatry 2012; 53: 1137-1144.
31. Gorna K, Jaracz K, Rybakowski F, Rybakowski J,. Determinants of objective and subjective quality of life in first-time-admission schizophrenic patients in Poland: A longitudinal study. Qual. Life Res. 2008; 17: 237-247.
32. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR,. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology 2006; 31: 2318-2325.
33. Baker SC, Rogers RD, Owen AM, et al. Neural systems engaged by planning: A PET study of the Tower of London task. Neuropsychologia 1996; 34: 515-526.
34. Gourovitch ML, Kirkby BS, Goldberg TE, et al. A comparison of rCBF patterns during letter and semantic fluency. Neuropsychology 2000; 14: 353-360.
35. Ohoyama K, Yamamura S, Hamaguchi T, et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011; 653: 47-57.
36. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010; 167: 1116-1124.
37. Harvey PD,. Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia. Innov. Clin. Neurosci. 2011; 8: 14-18.
38. Kinoshita T,. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study). Jpn. J. Clin. Psychopharmacol. 2008; 11: 135-153.
39. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 2012; 13: 318-378.